Related Articles
Continuous exposure of non‑small cell lung cancer cells with wild‑type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3
Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer
Successful treatment of non‑small‑cell lung cancer with afatinib and a glucocorticoid following gefitinib‑ and erlotinib‑induced interstitial lung disease: A case report
Presence of the minor EGFR T790M mutation is associated with drug-sensitive EGFR mutations in lung adenocarcinoma patients